Turkey is definitely fast emerging as a fresh hub for pharma developing. This year, CPhI Istanbul shall welcome more than 200 exhibitors from 23 Countries and over 4,000 visitors. The pharma marketplace in Turkey is currently valued at 14.6 billion Turkish Lira with CPhI Istanbul the integral gateway for companies seeking to deliver medicines throughout Central Asia, the Middle East, North Africa and Eastern European countries. An updated analysis report shall be launched at the 2015 event, providing attendees with vital information to help with making business decisions across this diversifying area. These services have been specifically made to help attendees obtain their individual business goals and to make on-site navigation easier.Related StoriesCrucial change in one DNA base predisposes children to aggressive form of cancerStudy shows uncommon HER2 missense mutations do not spread breasts cancer on their ownSausages With Antioxidants From Berries TO AVOID CancerIn their report, ‘Aristolactam-DNA adducts certainly are a biomarker of environmental contact with aristolochic acid,’ the investigators explain finding AL-DNA adducts in 70 % of the endemic UUC sufferers and in 94 % of individuals who carried ‘fingerprint’ mutations in TP53, a gene connected with many forms of malignancy. Neither the AL-DNA adducts nor the fingerprint TP53 mutations were detected in DNA extracted from tissues of UUC patients who lived beyond your region and who, therefore, did not eat bread baked from the Aristolochia-contaminated wheat.